<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677144</url>
  </required_header>
  <id_info>
    <org_study_id>HMC-HO-GI-0712</org_study_id>
    <nct_id>NCT00677144</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and
      Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin and oral fluoropyrimidines (capecitabine or S-1) are active agents for colorectal
      cancer. Recent a phase II trial of combination chemotherapy of oxaliplatin with S-1 (OS) and
      several phase II trial of combination chemotherapy of oxaliplatin with capecitabine (XELOX)
      demonstrated good activity and mild toxicity in advanced colorectal cancer. Oxaliplatin and
      S-1 or capecitabine have distinct mechanisms of action and no overlap of key toxicities.
      Furthermore, oxaliplatin and fluorouracil were shown to be highly synergistic, not only in
      preclinical models but also in subsequent clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, time to progression, and overall survival</measure>
    <time_frame>4.6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>OS (oxalipaltin+S-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OS (oxalipaltin+S-1)</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
    <arm_group_label>OS (oxalipaltin+S-1)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX (oxalipaltin+capecitabine)</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed colorectal adenocarcinoma, initially diagnosed or recurred

          -  Unresectable, locally advanced or metastatic

          -  At least one uni-dimensional measurable lesion by RECIST criteria

          -  Age 18 to 75 years old

          -  Estimated life expectancy ≥3 months

          -  ECOG performance status ≤2

          -  Adequate bone marrow function (WBCs ≥ 4,000/µL or absolute neutrophil count ≥
             1,500/µL, platelets ≥ 100,000/µL)

          -  Adequate kidney function (creatinine &lt; 1.5 mg/dL)

          -  Adequate liver function (bilirubin &lt; 2.0 mg/dL, transaminase levels &lt;2.5 times the
             upper normal limit)

          -  Written informed consent

        Exclusion Criteria:

          -  Other tumor type than adenocarcinoma

          -  Previous history of chemotherapy (exception : neoadjuvant or adjuvant chemotherapy
             without oxaliplatin)

          -  Presence of CNS metastasis, psychosis, or seizure

          -  Obvious bowel obstruction

          -  Evidence of serious gastrointestinal bleeding

          -  Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except
             for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix
             uteri

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Young Zang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasm</keyword>
  <keyword>S-1</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

